Evaluation of novel second-generation RSV and influenza rapid tests at the point of care
Acute respiratory infections represent common pediatric emergencies. Infection control warrants immediate and accurate diagnoses. In the past, first-generation respiratory syncytial virus (RSV) rapid tests (strip tests) have shown suboptimal sensitivities. In 2013, the Food and Drug Administration licensed a second-generation RSV rapid test providing user-independent readouts (SOFIA™-RSV) using automated fluorescence assay technology known to yield superior results with influenza rapid testing. We are reporting the first point-of-care evaluation of the SOFIA™-RSV rapid test. In the Charité Influenza-Like Disease Cohort, 686 nasopharyngeal samples were tested in parallel with SOFIA™-RSV and SOFIA™-Influenza A+B. Compared to real-time PCR, SOFIA™-RSV sensitivities/specificities were 78.6%/93.9%, respectively (SOFIA™-Influenza A: 80.6%/99.3%). Performance was greatest in patients below 2 years of age with a test sensitivity of 81.8%. RSV sensitivities were highest (85%) in the first 2 days of illness and with nasopharyngeal compared to nasal swabs (P=0.055, McNemar's test). Second-generation RSV and influenza rapid testing provides highly accurate results facilitating timely patient cohortation and management..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 81(2015), 3, Seite 171-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tuttle, Ryan [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.diagmicrobio.2014.11.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956559124 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956559124 | ||
| 003 | DE-627 | ||
| 005 | 20230517155939.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2014.11.013 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956559124 | ||
| 035 | |a (DE-599)GBVOLC1956559124 | ||
| 035 | |a (PRQ)c1345-35ef0a6a7abc829a5b6bcbbb3e5878d10b4105ac9fd71e0c05affc8e566c63a10 | ||
| 035 | |a (KEY)0121288520150000081000300171evaluationofnovelsecondgenerationrsvandinfluenzara | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Tuttle, Ryan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of novel second-generation RSV and influenza rapid tests at the point of care |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Acute respiratory infections represent common pediatric emergencies. Infection control warrants immediate and accurate diagnoses. In the past, first-generation respiratory syncytial virus (RSV) rapid tests (strip tests) have shown suboptimal sensitivities. In 2013, the Food and Drug Administration licensed a second-generation RSV rapid test providing user-independent readouts (SOFIA™-RSV) using automated fluorescence assay technology known to yield superior results with influenza rapid testing. We are reporting the first point-of-care evaluation of the SOFIA™-RSV rapid test. In the Charité Influenza-Like Disease Cohort, 686 nasopharyngeal samples were tested in parallel with SOFIA™-RSV and SOFIA™-Influenza A+B. Compared to real-time PCR, SOFIA™-RSV sensitivities/specificities were 78.6%/93.9%, respectively (SOFIA™-Influenza A: 80.6%/99.3%). Performance was greatest in patients below 2 years of age with a test sensitivity of 81.8%. RSV sensitivities were highest (85%) in the first 2 days of illness and with nasopharyngeal compared to nasal swabs (P=0.055, McNemar's test). Second-generation RSV and influenza rapid testing provides highly accurate results facilitating timely patient cohortation and management. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Inc. All rights reserved. | ||
| 650 | 4 | |a Influenza B virus - isolation & purification | |
| 650 | 4 | |a Influenza A virus - isolation & purification | |
| 650 | 4 | |a Respiratory Syncytial Viruses - isolation & purification | |
| 650 | 4 | |a Respiratory Syncytial Virus Infections - diagnosis | |
| 650 | 4 | |a Diagnostic Tests, Routine - methods | |
| 650 | 4 | |a Nasopharynx - virology | |
| 650 | 4 | |a Influenza, Human - diagnosis | |
| 700 | 1 | |a Weick, Anja |4 oth | |
| 700 | 1 | |a Schwarz, Wiebke Sabrina |4 oth | |
| 700 | 1 | |a Chen, Xi |4 oth | |
| 700 | 1 | |a Obermeier, Patrick |4 oth | |
| 700 | 1 | |a Seeber, Lea |4 oth | |
| 700 | 1 | |a Tief, Franziska |4 oth | |
| 700 | 1 | |a Muehlhans, Susann |4 oth | |
| 700 | 1 | |a Karsch, Katharina |4 oth | |
| 700 | 1 | |a Peiser, Christian |4 oth | |
| 700 | 1 | |a Duwe, Susanne |4 oth | |
| 700 | 1 | |a Schweiger, Brunhilde |4 oth | |
| 700 | 1 | |a Rath, Barbara |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d New York, NY : Elsevier, 1983 |g 81(2015), 3, Seite 171-176 |w (DE-627)130399507 |w (DE-600)604920-5 |w (DE-576)025082213 |x 0732-8893 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2015 |g number:3 |g pages:171-176 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2014.11.013 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25583129 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 81 |j 2015 |e 3 |h 171-176 | ||